Home » Stocks » ADXN

Addex Therapeutics Ltd. (ADXN)

Stock Price: $9.30 USD -0.31 (-3.23%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 67.54M
Revenue (ttm) 3.78M
Net Income (ttm) -11.91M
Shares Out 7.26M
EPS (ttm) -2.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $9.30
Previous Close $9.61
Change ($) -0.31
Change (%) -3.23%
Day's Open 9.78
Day's Range 9.30 - 9.78
Day's Volume 1,990
52-Week Range 8.01 - 37.52

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Addex Therapeutics (ADXN) has been struggling lately, but the selling pressure may be coming to an end soon.

1 week ago - Zacks Investment Research

Ge neva, Switzerland, May 5 , 20 2 1 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, tod...

2 months ago - GlobeNewsWire

KYIV, Ukraine--(BUSINESS WIRE)--Enamine Ltd. a provider of drug discovery services empowered with the world's largest collections of building blocks, fragments and screening compounds announced today th...

5 months ago - Business Wire

Genetic Technologies (NASDAQ: GENE) shares are trading higher after the company provided an update on its COVID-19 severity risk test, saying predictive capabilities improved 100% over age and sex alone...

Other stocks mentioned: OBLN, GENE
6 months ago - Benzinga

Addex Therapeutics (ADXN) stock is soaring higher on Thursday after announcing news concerning a clinical trial for its epilepsy drug. The post Epilepsy Drug News: Why Addex Therapeutics (ADXN) Stock Is...

6 months ago - InvestorPlace

Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...

6 months ago - GlobeNewsWire

About ADXN

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and col... [Read more...]

Industry
Pharmaceutical Preparation Manufacturing
Founded
2002
CEO
Tim Dyer
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
ADXN
Full Company Profile

Financial Performance

In 2020, ADXN's revenue was 3.61 million, an increase of 30.77% compared to the previous year's 2.76 million. Losses were -12.86 million, -13.00% less than in 2019.

Financial numbers in millions CHF.
Financial Statements